Comparative Pharmacology
Head-to-head clinical analysis: DOXYCYCLINE HYCLATE versus TETRACHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCYCLINE HYCLATE versus TETRACHEL.
DOXYCYCLINE HYCLATE vs TETRACHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline hyclate is a bacteriostatic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex. It also exhibits anti-inflammatory and anti-angiogenic properties.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily. For severe infections or certain indications, 100 mg every 12 hours.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
None Documented
None Documented
18-24 hours in patients with normal renal function; may increase to 24-48 hours in renal impairment; clinical context: allows once- or twice-daily dosing.
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Approximately 40% excreted unchanged in urine via glomerular filtration; 20-30% eliminated in feces via biliary secretion and nonbiliary routes; the remainder is metabolized. Enterohepatic circulation contributes to prolonged half-life.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic